TC Erciyes University

erciyes.edu.tr

Total trials

323

Active

68

Phase 3

4

Total enrollment

34,905

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Treatment as usual1
Root Canal Sealants1
root canal irrigation1
Stem Cell Product1
Bleeding and clots1
Inhalation anesthetic2
Sevoflurane2
Articaine With Epinephrine1
Corticosteroid1
a bovine-derived graft/xenograft enriched with hyaluronic acid1
a standart bovine-derived graft/xenograft1

Next readouts

  • 2025-02-01
  • 2025-02-28
  • 2025-03-01
  • 2025-06-01
  • 2026-04-01
  • 2026-06-05
  • 2026-08-15
  • 2027-08

Top conditions

  • Pain16
  • Anxiety10
  • Postoperative Pain10
  • Aromatherapy5
  • Comfort5
  • Analgesia4
  • Prostate Cancer4
  • Hemodialysis4

Frequently asked questions about TC Erciyes University

How many clinical trials does TC Erciyes University have on ClinicalTrials.gov?
TC Erciyes University is listed as the lead sponsor on 323 clinical trials in ClinicalTrials.gov, 68 of which are currently active (recruiting, enrolling, or ongoing).
How many of TC Erciyes University's trials are in Phase 3?
4 of TC Erciyes University's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does TC Erciyes University focus on?
TC Erciyes University's most-studied conditions on ClinicalTrials.gov are Pain, Anxiety, Postoperative Pain, Aromatherapy, Comfort.
When are TC Erciyes University's next clinical trial readouts?
TC Erciyes University has 8 upcoming primary-completion readouts tracked here; the soonest is “The Effect of Human Umbilical Cord Mesenchymal Stem Cells and Exosomes on the Healing of Postoperative Pain and Periapical Lesions in the Treatment of Apical Periodontitis: Randomized Controlled Clinical Study”, expected around 2025-02-01.